Experiencia de un programa para reducción de factores de riesgo cardiovascular en docentes de educación secundaria.: Experience of a program for the reduction of cardiovascular risk factors in secondary school teachers.

Raul Montalvo; Lorenzo  Castro; Tania Ingaruca; Armida Rojas; Salome Ochoa

doi:10.25176/RFMH.v24i4.6983

Authors

Raul Montalvo Universidad Nacional del Centro del Perú, Huancayo, Perú
Lorenzo Castro Hospital Regional Daniel Alcides Carrión, Huancayo, Perú
Tania Ingaruca Hospital Regional Daniel Alcides Carrión, Huancayo, Peru
Armida Rojas Universidad Nacional del Centro del Perú, Huancayo, Perú
Salome Ochoa Universidad Nacional del Centro del Perú, Huancayo, Perú

DOI:

https://doi.org/10.25176/RFMH.v24i4.6983

Keywords:

Body composition, educational intervention program, physical exercises, nutritional education, cardiovascular risk

Abstract

Introduction: Physical inactivity among secondary school teachers increases cardiovascular and metabolic risks, highlighting the need for effective intervention strategies. Objective: To compare changes in body composition, lipid profile, and blood pressure following a physical exercise and nutritional education program. Methods: A prospective observational study was conducted with 556 teachers, divided into a program group (274) and a no-program group (282). The program included guided weekly exercises and nutritional workshops over three months. Baseline and final measurements assessed weight, body mass index (BMI), blood pressure, lipid profile, and body composition using tetrapolar bioimpedance. Statistical analyses used Student's t-test to compare deltas between groups, with p<0.05 considered significant. Results: The program group showed reductions in systolic blood pressure (SBP) (-7.0±10.6 mmHg; p<0.001), body fat (-3.0±15.4%; p<0.001), and total cholesterol (-12.2±45.6 mg/dL; p=0.002). HDL cholesterol increased (+8.8±40.8 mg/dL; p=0.007). No significant changes were observed in these indicators in the no-program group. Weight and BMI did not vary significantly in either group. Conclusion: The program improved cardiovascular risk factors and body composition in teachers. Further studies are recommended to assess long-term sustainability and to consider follow-up strategies after program completion

Downloads

Download data is not yet available.

Author Biographies

Raul Montalvo, Universidad Nacional del Centro del Perú, Huancayo, Perú

Médico infectólogo

Lorenzo Castro, Hospital Regional Daniel Alcides Carrión, Huancayo, Perú

Clinical Pathologist

Tania Ingaruca, Hospital Regional Daniel Alcides Carrión, Huancayo, Peru

Medical Technologist

Armida Rojas, Universidad Nacional del Centro del Perú, Huancayo, Perú

Infectious Disease Physician

Salome Ochoa, Universidad Nacional del Centro del Perú, Huancayo, Perú

Physical Medicine and Rehabilitation Physician

References

Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52:447–56. [citado 23 Nov 2022]. Disponible en: https://www.sciencegate.app/document/10.1093/cid/ciq106

Wang Y, Huo P, Dai R, Lv X, Yuan S, Zhang Y, Guo Y, Li R, Yu Q, Zhu K. Convalescent plasma may be a possible treatment for COVID-19: A systematic review. Int Immunopharmacol. 2021 Feb;91:107262. [citado 24 Nov 2022]. Disponible en: https://www.sciencedirect.com/science/article/pii/S1567576920337292

Al-Tawfiq JA, Arabi Y. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19. Hum Vaccin Immunother. 2020 Dec 1;16(12):2973-2979. [citado 30 Dec 2022]. Disponible en: https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1793712

Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006 Oct 17;145(8):599-609. [citado 24 Nov 2022]. Disponible en: https://europepmc.org/article/MED/16940336

Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C, Wang ZS, Zhang ZH, Liu ZS. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis. 2020 Jun 16;222(1):38-43. doi: 10.1093/infdis/jiaa228. [citado 19 Dec 2022]. Disponible en: https://academic.oup.com/jid/article/222/1/38/5826985?login=false

González SE, Regairaz L, Ferrando NS, González Martínez VV, Salazar MR, Estenssoro E. Terapia con plasma de convalecientes en pacientes COVID-19 en la Provincia de Buenos Aires [Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires]. Medicina (B Aires). 2020;80(5):417-424. [citado 24 Nov 2022]. Disponible en:https://europepmc.org/article/MED/33048783

Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. [citado 13 Dec 2022]. Disponible en: doi: https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30141-9.pdf

Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, Stalenhoef-Schukken JE, Dofferhoff A, Ludwig I, et al.. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021 May 27;12(1):3189. [citado 16 Dec 2022]. Disponible en: https://www.nature.com/articles/s41467-021-23469-2

Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in COVID-19 disease: Clinical trial from eastern Anatolia. Transfus Apher Sci. 2020 Oct;59(5):102867. [citado 24 Nov 2022]. Disponible en: https://www.trasci.com/article/S1473-0502(20)30172-5/fulltext

Abolghasemi H, Eshghi P, Cheraghali A, Fooladi A, Moghaddam F, Imanizadeh S, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020 Oct;59(5):102875. [citado 11 Apr 2023]. Disponible en: https://www.trasci.com/article/S1473-0502(20)30180-4/fulltext

Galván CA, Toribio-Dionicio C, Álvarez-Ángeles M, Alama-Bazán O, Sánchez-Ramírez L. Transfusión de plasma convaleciente de pacientes con COVID-19 [Transfusion of convalescent plasma from patients with COVID -19]. Rev Peru Med Exp Salud Publica. 2020 Oct-Dec;37(4):746-754. [citado 30 Mar 2023]. Disponible en: https://scielosp.org/article/rpmesp/2020.v37n2/350-355/es/

Millat-Martinez P, Gharbharan A, Alemany A, Rokx C, Geurtsvankessel C, Papageorgiou G, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun. 2022 May 11;13(1):2583. doi: 10.1038/s41467-022-29911-3. Erratum in: Nat Commun. 2024 May 22;15(1):4352. PMID: 35546145; PMCID: PMC9095637.

Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, et al. Convalescent Plasma Antibody Levels and the Risk of Death from COVID-19. N Engl J Med. 2021 Mar 18;384(11):1015-1027. [citado 26 Dec 2022]. Disponible en: doi: https://www.nejm.org/doi/10.1056/NEJMoa2031893

Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020 Sep;92(9):1475-1483. [citado 29 Jun 2023]. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/jmv.25961

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. [citado 13 Nov 2022]. Disponible en: https://www.pnas.org/doi/10.1073/pnas.2004168117

Sánchez-Artigas R, Dorta-Contreras A. Algunas hipótesis científicas de la respuesta inmune como causa de daño inmunopatológico provocado en la COVID-19. Revista Cubana de Investigaciones Biomédicas. 2021 [citado 3 Apr 2023]; 40 (4) Disponible en: https://revibiomedica.sld.cu/index.php/ibi/article/view/1354

Montalvo R, Castro E, Chavez A. Alternative to traditional noninvasive ventilation using a modified snorkel mask in a patient with SARS-COV2: A case report. Can J Respir Ther. 2021 Feb 9;57:18-21.[citado 11 Sep 2022]. Disponible en: https://www.cjrt.ca/wp-content/uploads/cjrt-2020-039.pdf

Ministerio de Salud del Perú. DS N° 103-MINSA/2020/DIDGOT. Directiva Sanitaria que establece los lineamientos técnicos para la obtención de Plasma de Donantes Convalecientes de la enfermedad del Coronavirus 2019 (COVID-19). Directiva Sanitaria. Lima: Ministerio de Salud del Perú; 2020. [citado 22 Oct 2022]. . Disponible en: https://cdn.www.gob.pe/uploads/document/file/752913/RM_339-2020- MINSA.PDF.

Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MDL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Vidiella GP, Miyazaki EA, et al. PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in COVID-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619-629. [citado 11 Jan 2023]. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa2031304

Keitel V, Jensen B, Feldt T, Fischer JC, Bode JG, Matuschek C, Bölke E, Budach W, Plettenberg C, Scheckenbach K, Kindgen-Milles D, et al. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Trials. 2021 May 17;22(1):343. [citado 19 Dec 2022]. Disponible en: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05181-0

Libster R, Pérez Marc, Wappner D, S. Coviello, A. Bianchi, V. Braem, I. Esteban, M.T. Caballero, C. Wood, M. Berrueta, A. Rondan et al. Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults. N Engl J Med.. 2021, [citado 24 Nov 2022]. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa2033700

Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, Lesser ER, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv.. 2020 [citado 12 Mar 2023]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1

Medina-Gamero A, Regalado-Chamorro M. Eficacia y efectividad de las vacunas contra la COVID-19. Revista Cubana de Investigaciones Biomédicas [Internet]. 2021 [citado 3 Jun 2023]; 40 (3) Disponible en: https://revibiomedica.sld.cu/index.php/ibi/article/view/1853